Picture of Wimbledon Clinics

Wimbledon Clinics

BRI RESEARCHERS PINPOINT RA DRIVERS

Contact us for an appointment

*At Wimbledon Clinics we comply with the provisions of the General Data Protection Regulations (GDPR) and the Data Protection Act (UK). We will never share your data without your permission and we will only use your data how you’ve asked us to. Please let us know if you’d like to join our mailing list to receive updates about our specialist consultants, the latest treatments for orthopaedic and sports injuries and prevention tips for common injuries.

For more information, click here to view our privacy policy

Scientists from the Benaroya Research Institute (BRI) at Virginia Mason have identified the T-cells that promote rheumatoid arthritis (RA) by using state-of-the-art technology developed at the institute. The results of the study have been published online in the Arthritis & Rheumatology journal.

Through the use of BRI´s tetramer technology, the team was able to investigate whether individuals with RA had increased levels of T-cells or if the cells had unique characteristics, said Dr. Jane Buckner, lead researcher on the project and BRI associate director.

It is generally believed that RA is a T-cell mediated disease resulting from the immune system turning on its own tissues by mistake. The attack is primarily directed at the synovium – the membrane which lines joints. The resulting inflammation and joint pain are caused by fluid accumulation in the joints after the autoimmune response.

The BRI technology allowed the scientists to show that T-cells that are responsible for recognising proteins in joints were found in higher numbers in the blood of RA patients, Dr. Buckner said. Moreover, these T-cells possessed specific characteristics. The study showed that their number changed over time and as a result of the treatment provided to patients, Dr. Buckner added.

The unique technology provides insights into the development of RA, going as far back as the start of the disease. The effect of specific treatments in relation to immune responses directed to joints can now be analysed thanks to the solution.

RA is a disease that affects millions of people. Its treatment is associated with expensive drugs, which in turn carry the risk of side effects. Dr. Buckner believes that by providing treatment as early as possible and by solely targeting the cells responsible for the condition, scientists can achieve a higher success rate in fighting RA.